Evidence map›Paper›PMID 40573356›Full record

ReviewViruses2025

Viral Strategies and Cellular Countermeasures That Regulate mRNA Access to the Translation Apparatus.

Christopher U T Hellen

Abstract readReview
In one paragraph

Review in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Christopher U T HellenDepartment of Cell Biology, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA.ORCID 0000-0002-3982-2090

Funding

Alternative mechanisms of different stages in eukaryotic translationR01GM097014 · NIGMS · SUNY DOWNSTATE MEDICAL CENTER · PI HELLEN, CHRISTOPHER ULRICH TRISTRAM · 2012 to 2022
$2.6M
Mechanisms of SARS-CoV2 translation initiation and shut-off of cellular protein synthesisR21AI166944 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI HELLEN, CHRISTOPHER ULRICH TRISTRAM, PESTOVA, TATYANA V · 2022 to 2023
$446k
IRES-mediated initiation of picornavirus translationR21AI188505 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI CHRISTOPHER Ulrich Tristram HELLEN · 2025 to 2026
$441k
NIAID NIH HHS R21 AI166944NIAID NIH HHS R21 AI188505NIGMS NIH HHS R01 GM097014
6 · The paper itself

Abstract

The papers introduced in the Commentary present new insights and review aspects of current knowledge concerning the competition between viruses and their hosts for the cellular translation apparatus. Viruses depend on this apparatus and utilize diverse mechanisms to usurp it for the translation of viral mRNAs and to suppress synthesis of cellular proteins. Virus-induced modification of translation factors, selective abrogation of mRNA binding to ribosomes and degradation of cellular mRNAs all impair elements of the innate immune response, thereby undermining host defenses against infection. Various cellular mechanisms prevent translation of viral mRNAs, by modifying components of the translation apparatus to effect a generalized shut-off of translation or by binding of host proteins to viral mRNAs to induce their degradation or to prevent their engagement with the translation apparatus. Viruses have in turn evolved countermeasures to evade these defenses, for example by encoding proteins that impair the activity of host factors or via alterations in the sequence and structure of viral mRNAs. Such changes enable viral mRNAs to avoid recognition by host factors or to support translation initiation by specialized mechanisms that involve only a subset of the factors that are required by cellular mRNAs.

Indexed as

Host-Pathogen InteractionsProtein BiosynthesisRNA, MessengerRNA, ViralVirus DiseasesVirusesAnimalsHumansRibosomesRNA, MessengerRNA, Viralcaliciviruscoronavirusinterferon-stimulated geneIRESITAFmRNA translationpicornaviruspoxvirusShiftlesstranslational control

Identifiers

PMID40573356
PMCPMC12197335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.